Tag: Prescription Drugs
Four-Month Rifapentine Regimen With Moxifloxacin Noninferior for TB
Rifapentine-based regimen with moxifloxacin noninferior to six-month control regimen of rifampin, isoniazid, pyrazinamide, ethambutol
Exercise, Liraglutide Combo Superior for Weight Loss Maintenance
Weight loss greater compared with exercise alone, and decrease in body fat percentage greater compared with either strategy alone
Medication May Ease ADHD Symptoms in Preschool-Aged Children
Symptoms are reduced in a majority of preschool-aged children who initiate therapy with α2-adrenergic agonists or stimulants for ADHD
Farxiga Approved to Reduce Risk for CKD Progression
SGLT2 inhibitor approved for patients with CKD to prevent kidney function decline, kidney failure, CV death, hospitalization for heart failure
Bimekizumab Tops Secukinumab for Plaque Psoriasis
In second study, bimekizumab showed noninferiority and superiority to adalimumab for moderate-to-severe disease
Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
Stabilization of lung function independent of the extent of quantitative radiographic interstitial lung disease or fibrosis at baseline
FDA Approves Immunotherapy for dMMR Endometrial Cancer
Jemperli approved for dMMR endometrial cancer that progressed after platinum-containing chemotherapy treatment
Sacituzumab Govitecan Treats Metastatic Triple-Negative Breast Cancer
Progression-free, overall survival prolonged with sacitizumab govitecan versus single-agent chemotherapy
Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
FDA granted Opdivo first approval of immunotherapy for first-line treatment of advanced or metastatic gastric cancer
Gender, Race Affects Access to SGLT2-Inhibitor Therapy for T2DM
Women, Black or Asian patients less likely to receive sodium-glucose cotransporter 2 inhibitor treatment for type 2 diabetes